Clinical trial · Observational
Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery
Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery: A Retrospective Multi-center Study (EarlyLC-RW)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of early-stage lung cancer patients who have received surgery using the real-world data. The main questions it aims to answer are: * What is the best surgical strategy for patients with early-stage lung cancer? * What are the risk factors for early-stage lung cancer? Participants will receive surgery and the study will analyze the real-world data.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lobectomy | Other | — | UNRESOLVED |
| Sublobar resection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Sublobar resection group
- description
- Patients in this group have received Sublobar resection.
- interventionNames
- Other: Sublobar resection
- label
- Lobectomy group
- description
- Patients in this group have received lobectomy.
- interventionNames
- Other: Lobectomy
Primary outcomes (1)
- measure
- Disease-free survival(DFS)
- timeFrame
- Defined as the time from the date of surgery until the date of first documented progression or death (by any cause in the absence of recurrence), whichever came first, assessed up to 10 years.
- description
- Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged between 18 and 85; 2. Did not receive neoadjuvant therapy before surgery; 3. No history of radiation therapy; 4. Eastern Cooperative Oncology Group (ECOG) score is 0-1; 5. Have complete clinically relevant information including imaging data; 6. All patients underwent relevant preoperative examinations; 7. Stage I lung cancer (International Association for the Study of Lung Cancer/The Union for International Cancer Control staging eighth edition); Exclusion Criteria: 1. Have previously received chemotherapy, radiotherapy and other anti-tumor therapy; 2. Data loss and error in medical records due to human/objective reasons.
References
Publications (0)
Data not yet available